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Context. HypovitaminosisD frequently occurs in early life and increaseswith age. VitaminDhas been suggested to influence cardiac
performance and N-terminal-pro-type B natriuretic peptide (NT-proBNP) release in adults with heart failure.Objectives. To assess
the vitamin D status and the impact of hypovitaminosis D on circulating NT-proBNP levels in young patients with congenital heart
defects (CHD). Design and Patients. This cross-sectional study included the assessment of serum 25-hydroxyvitamin D (25OHD),
parathyroid function markers, and NT-proBNP levels in a series of 230 young in-patients (117 females, 113 males; 6.4 (4.0–9.1) years
(median, interquartile range)) with CHD. Results. Serum 25OHD levels <20 ng/mL were detected in 55.3% of patients. Optimal
25OHD levels (>30 ng/mL) occurred in 25% of patients. Serum 25OHD levels inversely correlated with age (𝑟 = −0.169, 𝑃 = 0.013)
and height standard deviation score (𝑟 = −0.269, 𝑃 = 0.001). After correction for age, 25OHD negatively correlated with serum
PTH levels (𝛽 = −0.200, 𝑃 = 0.002). PTH levels above the upper quartile (44 pg/mL) occurred in 32% of hypovitaminosis D
patients. Serum NT-proBNP levels were not correlated with 25OHD and PTH levels. Conclusions. Half of the young CHD patients
were diagnosed with 25OHD deficiency and a third of hypovitaminosis D patients experienced hyperparathyroidism. Nonetheless,
serum NT-proBNP levels were not associated with hypovitaminosis D as well as hyperparathyroidism.
1. Introduction
Congenital heart defects (CHD) occur in 0.5–0.9% of new-
borns and survival is substantially improved in the last
decades [1–5]. From a pathophysiologic standpoint, CHD
may be characterized by (1) increased volume overload
(i.e., defects characterized by left-to-right shunt, such as
ventricular septal defect, patent ductus arteriosus, truncus
arteriosus, atrial septal defect, and atrioventricular septal
defects); (2) pressure overload involving the left ventricle (i.e.,
aortic stenosis and aortic coarctation) or the right ventricle
(i.e., tetralogy of Fallot and pulmonary stenosis); (3) complex
cyanotic CHD (i.e., univentricular heart and transposition of
the great arteries).
The N-terminal-pro-type B natriuretic peptide (NT-
proBNP) is 76 amino acids derived from cleavage of a
prohormone of 108 amino acids synthesized and released by
cardiomyocytes. NT-proBNP can be used as an adjunctive
marker in the integrated screening, diagnosis, management,
and follow-up of children with heart failure caused by
various acquired and congenital heart diseases [6]. The
natriuretic peptides, NT-proBNP and BNP, correlate with
various indexes of disease severity in childrenwith congenital
heart defects. The measurement of the circulating cardiac
biomarkers BNP and NT-proBNP is now recommended by
international guidelines [7, 8].
Hypovitaminosis D is prevalent worldwide: around 37%
of studies evaluating the vitamin D status in various
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populations reported mean values below 20 ng/mL [9]. Pedi-
atric patients with congenital heart defects might be a popu-
lation at high risk of hypovitaminosis D due to their chronic
disease and to the reduced exposure to sunlight. Vitamin D is
key component of the calcium metabolism. Calcium and the
calciotropic hormones, vitamin D and parathormone (PTH),
exert direct and indirect effects on cardiomyocytes. Cal-
cium dyshomeostasis associated with hypocalcemia, hypovi-
taminosis D, and secondary hyperparathyroidism can lead
to the development of dilated cardiomyopathy with life-
threatening consequences in both infants [10, 11] and adults
[12]. Moreover, cardiomyocytes express both the vitamin D
receptors and the PTH receptors (PTHR1), and studies in
rodents have shown that vitamin D protects against cardiac
hypertrophy andmyocardial dysfunction [13–16]. In line with
experimental data, vitamin D deficiency has been associated
with a poor prognosis in adult patients with heart failure [17],
and circulating PTH levels are related with an increased risk
of cardiovascular events and mortality [18–20].
In the present study, we tested the hypothesis that vitamin
D status might influence cardiac performance and therefore
the circulating NT-proBNP levels in young patients with
congenital heart defects. We investigated (1) the vitamin D
status and (2) the correlations of calciummetabolismmarkers
with serum NT-proBNP levels in a consistent series of young
patients with various congenital heart defects.
2. Patients and Methods
2.1. Study Population. Two hundred thirty young patients
(117 females, 113 males; 6.4 (4.0–9.1) years (median age,
interquartile range)) with CHD, referred to the Policlinico
San Donato Pediatric Cardiosurgery between January 2007
and January 2009, were consecutively enrolled. All patients
were studied at the admission to be evaluated for congenital
heart defects and to undergo open or transcatheter surgical
correction when haemodynamically significant CHD was
diagnosed. In particular, 153 patients harboured defects deter-
mining increased volume overload (i.e., defects characterized
by left-to-right shunt, such as ventricular septal defect, patent
ductus arteriosus, truncus arteriosus, atrial septal defect,
and atrioventricular septal defects); 62 patients had heart
defects with pressure overload involving the left ventricle (i.e.,
aortic stenosis and aortic coarctation) or the right ventricle
(i.e., tetralogy of Fallot and pulmonary stenosis); and 15
patients were affected with complex cyanotic CHD (i.e.,
univentricular heart and transposition of the great arteries).
Anamnestic and anthropometric parameters were
recorded. Height was evaluated by height standard deviation
score (HSDS) related to Italian growth curves for children
aged 2–20 years [21]. HSDS for infants aged 0–2 years was
calculated by using the Kabi-Pharmacia Growth Calculator,
based on the British standards. Weight was evaluated by
Weight-to-Height Index (WHP) expressed as the percentage
of the median of the British standards using the Kabi-Phar-
macia Growth Calculator. Clinical data are shown in
Table 1. Exclusion criteria were considered overt cyanotic
status, acute or chronic kidney failure, liver failure,
infective and inflammatory diseases, acquired or metabolic
cardiomyopathy, concurrent treatment with diuretics, amio-
darone and steroids, ongoing calcium and/or vitamin D
supplementation in the last 6months, overt hypoparathyroid-
ism, and overt or mild hypothyroidism.
Informed consent for personal data and blood collection
was obtained by parents of all patients. The study was
approved by the local ethical committee.
2.2.Measurements. Venous blood sampling was collected the
day before the diagnostic procedure after an overnight fast-
ing, and biochemical and hormonal markers were measured
in all patients. Serum calcium, phosphate, magnesium, and
creatinine were measured by routine assays. Serum calcium
levels were corrected for the serum albumin concentrations
according to the formula: serum total calcium (mg/dL) − 0.8
× [serum albumin (g/dL) − 4.0]. Serum albumin concentra-
tions were within the normal range in all patients indicating
the absence of malnutrition. Ionized calcium concentrations
were assayed by Liquichek Blood Gas (IL Synthesis Series,
Bio-Rad Laboratories, Segrate, MI, Italy). Serum 25OHD
concentrations were measured by a chemiluminescent assay
(LIAISON test, DiaSorin Inc., Stillwater, MN, USA) with
mean intra- and interassay coefficients of variation (CV) of
4.5% and 7.5%, respectively. Serum NT-proBNP and PTH
were measured by Electrochemiluminescence on an Elecsys
2010 (Roche Diagnostics, Mannheim, Germany).
2.3. Statistical Analysis. Continuous parameters following
a nonnormal distribution were presented as median and
interquartile range (IQ). Normally distributed parameters
were presented asmean± standard deviation; categorical data
were given as percentages. Based on serum 25OHD concen-
trations, we formed four categories according to widely used
cut-off values [22–24]: severe deficiency, less than 10.0 ng/mL;
moderate deficiency, 10.0–19.9 ng/mL; insufficiency, 20.0–
29.9 ng/mL; and 25OHD optimal range, 30.0–100.0 ng/mL.
For nanomoles per liter, multiply by 2.496. Serum 25OHD,
PTH, and NT-pro-BNP concentrations were logarithmically
transformed before being used in parametric procedures.
Comparisons among CHD groups were performed by anal-
ysis of variance (ANOVA) with 𝑃 for linear trend for con-
tinuous parameters or ANOVA on ranks for nonparametric
data. A 𝜒2 test was performed for categorical variables. Sim-
ple correlation analyses (Pearson or Spearman correlations
where appropriated) and multiple linear regression analyses
including several independent variables were performed to
examine whether 25OHD levels were associated with NT-
pro-BNP levels. A 𝑃 value <0.05 was considered statistically
significant. Data were analysed using SPSS 22.0 statistical
package (SPSS 22.0 Inc., Chicago, IL).
3. Results
3.1. Vitamin D Status in Young CHD Patients. Assessment
of serum 25OHD levels in all CHD patients showed a high
prevalence of vitamin D deficiency: serum 25OHD levels <
20 ng/mL were detected in 55.3% of young CHD patients and
severe vitamin D deficiency (25OHD < 10 ng/mL) occurred
in 17.6% of patients. Adequate vitamin D levels, defined as
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Table 1: Clinical, biochemical, and hormonal features according to the vitamin D status in young CHD patients.
Markers
Serum 25OHD levels
𝑃
<10.0 ng/mL 10.0–19.9 ng/mL 20.0–30.0 ng/mL >30.0 ng/mL
𝑁 33 88 48 61
Age (years) 8.3(5.6–11.2)
5.8
(3.8–9.0)∗
7.1
(4.6–9.4)
5.7
(2.8–8.7)∗
0.02
Male/female 12/21 43/45 23/25 35/26 ns
HSDS 0.02(−0.54–0.65)
−0.25
(−1.09–0.77)
−0.06
(−1.4–0.31)
−0.83
(−1.6–0.11)∗
0.002
𝑊/𝐻 (%) 101.5(91.5–112.5)
97.0
(93.0–107.0)
102.0
(94.0–114.5)
95.0
(88.0–104.5)§
0.03
Creatinine
(mg/dL)
0.46
(0.37–0.57)
0.41
(0.36–0.51)∗
0.45
(0.38–0.51)
0.40
(0.32–0.45)∗
0.01
Alb/calcium
(mg/dL)
9.07
(8.80–9.40)
8.97
(8.79–9.25)
9.04
(8.72–9.31)
9.02
(8.80–9.36)
ns
Ionized Ca (mmol/L) 1.19(1.07–1.25)
1.19
(1.13–1.26)
1.22
(1.08–1.30)
1.21
(1.13–1.30)
ns
Magnesium
(mg/dL)
2.08
(1.98–2.14)
2.07
(1.95–2.19)
2.15
(1.98–2.23)
2.05
(1.97–2.15)
ns
Phosphate
(mg/dL)
4.86
(4.37–5.38)
5.18
(4.75–5.67)
5.28
(4.77–5.65)
5.11
(4.69–5.67)
ns
PTH
(pg/mL)
34.0
(21.5–52.5)
31.0
(24.2–48.7)
31.5
(23.2–43.5)
27.0
(17.5–38.0)∗
0.003
NT-proBNP
(ng/mL)
104.6
(63.2–179.7)
89.1
(43.7–149.2)
129.7
(57.5–283.3)
128.3
(62.9–193.6)
ns
∗
𝑃 < 0.05 versus 25OHD< 10 ng/dL; §𝑃 < 0.05 versus 25OHD20–30 ng/dL; ns, not significant; Alb/calcium, albumin-corrected calcium;𝑊/𝐻, weight/height;
HSDS, height standard deviation score; ionized Ca, ionized calcium.
serum25OHD levels> 30 ng/mL,were detected in about one-
forth of the CHD patients. Vitamin D status did not differ
between males and females nor among CHD groups. Young
CHD patients with 25OHD <10 ng/mL did not complain for
symptoms of rickets (bowed legs, thickened wrists and ankle,
and breastbone projection).
Serum 25OHD levels negatively correlated with age (𝑟 =
−0.169, 𝑃 = 0.013) (Figure 1(a)) and with height SDS (𝑟 =
−0.269, 𝑃 = 0.001) (Figure 1(b)), also after adjustment for
age (𝛽 = −0.200, 𝑃 = 0.002). Accordingly, CHD patients with
severe vitamin D deficiency (<10 ng/mL) were older, heavier,
and with higher median PTH levels than patients with an
optimal vitamin D status (>30 ng/mL) (Table 1), while serum
25OHD levels did not differ among the three CHD groups
identified according the underlying congenital heart defect
(Table 2).
3.2. Parathyroid Function in Young CHD Patients. Overt
hypocalcemia and hypomagnesemia were considered exclu-
sion criteria. Hypercalcemia, defined as elevated levels of
serum albumin-corrected calcium and ionized calcium, was
not detected in any patients. Hyperparathyroidism, defined
as serum PTH levels in the higher quartile (>44 pg/mL), was
diagnosed in 56 out of 230 CHD patients (24.0%). Serum
PTH levels positively correlated with 25OHD levels (𝑟 =
−0.216, 𝑃 = 0.001; Figure 1(c)) also after adjustment for age
(𝛽 = −0.200, 𝑃 = 0.002). In the present series, renal function
was conserved in all CHD patients as confirmed by serum
creatinine levels in the normal range.
3.3. Effect of Vitamin D Status and PTH Secretion Alterations
on Serum NT-proBNP Levels. Serum NT-proBNP levels
ranged from 5.1 to 5529.0 ng/mL in the present series of young
CHD patients. Serum NT-proBNP levels did not show any
significant correlation with age and did not differ among
the different CHD groups (Table 2). Moreover, significant
correlations between serum NT-pro-BNP levels and 25OHD
(Figure 2(a)) as well as PTH and albumin-corrected calcium
failed to be detected (Figure 2(b)).
4. Discussion
Circulating NT-proBNP is a cardiac biomarker for diagnosis,
prognosis, and therapeutic monitoring. Data available so far
in pediatric patients support the NT-proBNP measurement
in specific cases [6]. Serum 25OHD and/or PTH levels
have been shown to be independently associated with all
cause and cardiovascular mortality in adult patients with
heart failure [25–28]. Moreover, previous studies reported
a negative correlation between serum 25OHD levels and
NT-proBNP levels in adult patients with coronary artery
diseases and heart failure [27, 29, 30]. Indeed, findings are
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Table 2: Clinical, biochemical, and hormonal features according the CHD type in young CHD patients.
Markers CHD1 CHD2 CHD3 𝑃
𝑛 153 62 15
Age (years) 6.4(4.3–9.2)
7.5
(3.8–10.3)
5.4
(2.6–6.7) ns
Male/female 65/88 35/27 11/4 ns
HSDS −0.13(−1.07–0.59)
−0.54
(−1.42–0.44)
−0.92
(−2.29–0.42) ns
𝑊/𝐻 (%) 98.0(92.0–107.0)
98.5
(93.0–110.3)
93.0
(84.0–107.0) ns
Creatinine
(mg/dL)
0.42
(0.36–0.50)
0.44
(0.36–0.55)
0.41
(0.35–0.45) ns
Alb/calcium
(mg/dL)
9.02
(8.80–9.30)
9.06
(8.80–9.33)
8.81
(8.72–9.60) ns
25OHD
(ng/mL)
19.0
(12.8–30.0)
21.3
(12.5–33.4)
17.9
(11.9–30.7) ns
PTH
(pg/mL)
31.0
(22.0–44.5)
28.5
(20.5–41.0)
35.0
(26.0–59.0) ns
NT-proBNP
(ng/mL)
104.6
(60.1–182.5)
109.8
(54.7–200.9)
70.0
(41.0–97.9) ns
ns, not significant; Alb/calcium, albumin-corrected calcium;𝑊/𝐻, weight/height; HSDS, height standard deviation score; ionized Ca, ionized calcium.
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Figure 1: Correlations of serum 25OHD levels with clinical and hormonal markers in young CHD patients. (a) Log 25OHD levels were
negatively correlated with age. (b) Log 25OHD levels negatively correlated with height SDS. (c) Log 25OHD levels negatively correlated with
Log PTH levels. Best-fit line (continuous lines) and 95% intervals of confidence (dashed lines) were shown.
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Figure 2: Lack of correlations of serum NT-proBNP levels and 25OHD and PTH levels in young CHD patients. (a) Log 25OHD levels were
not correlated with Log NT-proBNP levels. (b) Log PTH levels were not correlated with Log NT-proBNP levels.
controversial as an investigation in the setting of adult post-
acute myocardial infarction failed in detecting an association
between nutritional vitamin D status and NT-proBNP levels
[31]. Moreover, a recent interventional study reported any
significant effect of oral vitamin D supplementation on
circulating NT-proBNP levels in adult peritoneal dialysis
patients [32].
In the present series of young CHD patients, we failed
in detecting such a relationship between 25OHD and NT-
proBNP levels as well as between PTH and NT-proBNP lev-
els, though in the present young CHD cohort vitamin D defi-
ciency and mild hyperparathyroidism frequently occurred.
Data about vitamin D status in young patients with CHD
are scanty: Avitabile et al. [33] reported vitamin D deficiency,
defined as serum 25OHD levels lower than 20 ng/mL, in 25%
of a small series of children and young adults (𝑛 = 50)
with Fontan physiology, while McNally et al. [34] reported
hypovitaminosis D in about 40% of 58 young CHD patients.
This is the first study investigating the preoperatively
vitamin D status in a consistent series of young patients
with various congenital heart defects. In the present series,
hypovitaminosis D occurred in half of the patients. Children
and adolescents have been reported to be potentially at
high risk for vitamin D deficiency [35, 36]. In Europe,
where very few foods are fortified with vitamin D, children
would appear to be at especially high risk [34]. Indeed, the
prevalence of hypovitaminosis D in the present series of
CHD young patients was similar to that found in a cohort
of Italian healthy children and adolescents [37], suggesting
that most of the CHD conditions do not represent a risk
factor for the development of hypovitaminosis D in children
and adolescents. This point is further supported by the lack
of significant differences in median 25OHD levels among
the three pathophysiological CHD groups. Moreover, serum
25OHD levels were inversely related to CHD patients’ age
and height, suggesting, in line with a previous report [38],
that older children and adolescents as well as subjects with
overweight experience more frequently hypovitaminosis D.
Serum 1,25-dihydroxyvitamin D levels have been sug-
gested to strongly and independently predict cardiovas-
cular mortality in adult patients with chronic heart fail-
ure [39]. Therefore, 1,25-dihydroxyvitamin D levels might
be more sensitive in detecting the correlation with NT-
proBNP levels in young CHD patients; unfortunately, 1,25-
dihydroxyvitaminD determinations were not available in the
present series of CHD patients.
The serum PTH threshold of 44 pg/mL, corresponding to
the upper quartile of the PTH distribution in the young CHD
patients, has been chosen to detect mild parathyroid function
activation induced by vitamin D deficiency in young subjects
with normal renal function [40, 41]. Indeed, PTH levels in
healthy children and adolescents have been found to cover a
narrower range than the adult values [42]. Considering this
PTH threshold, about one-third of hypovitaminosis D young
CHD patients showed hyperparathyroidism. Sustained rises
in plasma PTH lead to intracellular Ca2+ overloading in
diverse cells, including cardiomyocytes [43]. In turn, elevated
energy ATP stores become depleted and ATPase-dependent
Ca2+ efflux reduced, together with an induction of oxidative
stress that can threaten cardiomyocyte survival. Though
the experimental and clinical data suggest an association
between NT-proBNP and PTH levels and support their role
as predictors of clinical outcomes in adult with cardiovas-
cular diseases, any significant association could be detected
betweenNT-proBNP and PTH levels in youngCHDpatients.
In conclusion, vitamin D deficiency occurred in half
of the young CHD patients and mild hyperparathyroidism
could be detected in quarter of the patients. The circu-
lating biomarker NT-proBNP was not related with both
vitamin D status and PTH increases, suggesting that calcium
metabolism aberrations might not affect circulating NT-
proBNP levels in young CHD patients.
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